AbbVie Inc (ABBV)
165.72
+1.06
(+0.64%)
USD |
NYSE |
Apr 19, 14:55
AbbVie Cash from Operations (TTM): 22.84B for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 22.84B |
September 30, 2023 | 25.51B |
June 30, 2023 | 25.54B |
March 31, 2023 | 24.23B |
December 31, 2022 | 24.94B |
September 30, 2022 | 22.59B |
June 30, 2022 | 22.92B |
March 31, 2022 | 22.81B |
December 31, 2021 | 22.78B |
September 30, 2021 | 22.56B |
June 30, 2021 | 20.45B |
March 31, 2021 | 18.65B |
December 31, 2020 | 17.59B |
September 30, 2020 | 16.01B |
June 30, 2020 | 14.73B |
March 31, 2020 | 14.12B |
December 31, 2019 | 13.32B |
September 30, 2019 | 13.44B |
June 30, 2019 | 13.41B |
March 31, 2019 | 13.80B |
December 31, 2018 | 13.43B |
September 30, 2018 | 12.62B |
June 30, 2018 | 11.37B |
March 31, 2018 | 10.50B |
December 31, 2017 | 9.96B |
Date | Value |
---|---|
September 30, 2017 | 8.917B |
June 30, 2017 | 7.10B |
March 31, 2017 | 7.015B |
December 31, 2016 | 7.041B |
September 30, 2016 | 7.463B |
June 30, 2016 | 8.164B |
March 31, 2016 | 8.078B |
December 31, 2015 | 7.535B |
September 30, 2015 | 4.994B |
June 30, 2015 | 4.625B |
March 31, 2015 | 4.51B |
December 31, 2014 | 3.549B |
September 30, 2014 | 5.372B |
June 30, 2014 | 5.384B |
March 31, 2014 | 5.704B |
December 31, 2013 | 6.267B |
September 30, 2013 | 5.963B |
June 30, 2013 | 6.414B |
March 31, 2013 | 5.938B |
December 31, 2012 | 6.345B |
September 30, 2012 | 6.453B |
June 30, 2012 | 5.973B |
March 31, 2012 | 6.559B |
December 31, 2011 | 6.247B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
13.32B
Minimum
Dec 2019
25.54B
Maximum
Jun 2023
19.92B
Average
22.56B
Median
Sep 2021
Cash from Operations (TTM) Benchmarks
Amgen Inc | 8.471B |
Gilead Sciences Inc | 8.006B |
Immunogen Inc (DELISTED) | -197.89M |
Johnson & Johnson | 22.79B |
Eli Lilly and Co | 4.240B |